外科理论与实践 ›› 2024, Vol. 29 ›› Issue (05): 396-400.doi: 10.16139/j.1007-9610.2024.05.05
收稿日期:
2024-07-19
出版日期:
2024-09-25
发布日期:
2025-01-23
通讯作者:
康亮,E-mail: kangl@mail.sysu.edu.cn基金资助:
ZHOU Yihang, ZENG Ziwei, KANG Liang()
Received:
2024-07-19
Online:
2024-09-25
Published:
2025-01-23
摘要:
全直肠系膜切除术(TME)是进展期中低位直肠癌治疗的金标准。然而,由之而来的手术并发症发生及相应器官功能受损限制了该术式的应用。近年来,随着新辅助放化疗的进步以及免疫治疗的逐步应用,直肠癌新辅助治疗后病理完全缓解率不断提升。对于这部分病人是否仍需行TME产生质疑,因此,不行根治性手术的器官保留策略开始进入临床研究应用。目前有限的研究表明,无论是观察等待还是局部切除,虽然在部分病人中获得良好的长期生存并减少手术并发症发生和受损缺陷的优势,但还有临床完全缓解难以精准评估以及局部再发率过高导致长期生存下降等不足。仍需要进一步加强器官保留策略的探索研究,针对临床病例谨慎思考,以免该策略由“馅饼”变成“陷阱”。
中图分类号:
周驿航, 曾子威, 康亮. 直肠癌治疗器官保留策略:馅饼还是陷阱?[J]. 外科理论与实践, 2024, 29(05): 396-400.
ZHOU Yihang, ZENG Ziwei, KANG Liang. Organ preservation strategies for rectal cancer treatment: tarts or trap?[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 396-400.
[1] | 闫超, 陕飞, 李子禹. 2020年中国与全球结直肠癌流行概况分析[J]. 中华肿瘤杂志, 2023, 45(3):221-229. |
YAN C, SHAN F, LI Z Y. Prevalence of colorectal cancer in 2020: a comparative analysis between China and the world[J]. Chin J Oncol, 2023, 45(3):221-229. | |
[2] | BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10):1139-1167. |
[3] | HEALD R J. The ‘Holy Plane’ of rectal surgery[J]. J R Soc Med, 1988, 81(9):503-508. |
[4] | GARFINKLE R, BOUTROS M. Low anterior resection syndrome: predisposing factors and treatment[J]. Surg Oncol, 2022,43:101691. |
[5] |
KEANE C, WELLS C, O'GRADY G, et al. Defining low anterior resection syndrome: a systematic review of the literature[J]. Colorectal Dis, 2017, 19(8):713-722.
doi: 10.1111/codi.13767 pmid: 28612460 |
[6] |
BATTERSBY NJ, JUUL T, CHRISTENSEN P, et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study[J]. Dis Colon Rectum, 2016, 59(4):270-280.
doi: 10.1097/DCR.0000000000000552 pmid: 26953985 |
[7] |
FLEMING C A, CULLINANE C, LYNCH N, et al. Urogenital function following robotic and laparoscopic rectal cancer surgery: meta-analysis[J]. Br J Surg, 2021, 108(2):128-137.
doi: 10.1093/bjs/znaa067 pmid: 33711141 |
[8] | SAUER R, BECKER H, HOHENBERGER W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17):1731-1740. |
[9] | KAPITEIJN E, MARIJNEN C A, NAGTEGAAL I D, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer[J]. N Engl J Med, 2001, 345(9):638-646. |
[10] |
Globalsurg Collaborative and National Institute for Health Research Global Health Research Unit On Global Surgery. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries[J]. Lancet, 2021, 397(10272):387-397.
doi: 10.1016/S0140-6736(21)00001-5 pmid: 33485461 |
[11] |
OVERMAN M J, MCDERMOTT R, LEACH J L, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017, 18(9):1182-1191.
doi: S1470-2045(17)30422-9 pmid: 28734759 |
[12] | HABR-GAMA A, PEREZ R O, NADALIN W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results[J]. Ann Surg, 2004, 240(4):711-717;discussion717-718. |
[13] | VAN DER VALK M J M, HILLING D E, BASTIAANNET E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139):2537-2545. |
[14] | HABR-GAMA A, GAMA-RODRIGUES J, SÃO JULIÃO G P, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4):822-828. |
[15] |
LIN W, WEE I J Y, SEOW-EN I, et al. Survival outcomes of salvage surgery in the watch-and-wait approach for rectal cancer with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J]. Ann Coloproctol, 2023, 39(6):447-456.
doi: 10.3393/ac.2022.01221.0174 pmid: 38185947 |
[16] |
LIM L, CHAO M, SHAPIRO J, et al. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal[J]. Dis Colon Rectum, 2007, 50(12):2032-2039.
pmid: 17896138 |
[17] | ARAUJO R O, VALADÃO M, BORGES D, et al. Non-operative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study[J]. Eur J Surg Oncol, 2015, 41(11):1456-1463. |
[18] |
FERNANDEZ L M, SÃO JULIÃO G P, RENEHAN A G, et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the international watch and wait database[J]. Dis Colon Rectum, 2023, 66(1):41-49.
doi: 10.1097/DCR.0000000000002494 pmid: 36515514 |
[19] | GARCIA-AGUILAR J, RENFRO L A, CHOW O S, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial[J]. Lancet Oncol, 2015, 16(15):1537-1546. |
[20] |
RULLIER E, ROUANET P, TUECH J J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2017, 390(10093):469-479.
doi: S0140-6736(17)31056-5 pmid: 28601342 |
[21] |
VERSEVELD M, DE GRAAF E J, VERHOEF C, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study)[J]. Br J Surg, 2015, 102(7):853-860.
doi: 10.1002/bjs.9809 pmid: 25847025 |
[1] | 王虹晓, 苏琪莹, 阎骅. 结直肠癌预后生物标志物研究进展[J]. 内科理论与实践, 2024, 19(05): 337-341. |
[2] | 陈芳倩, 冯雯卿, 赵敬坤, 宗雅萍, 陆爱国. T1期结肠直肠癌淋巴结转移相关危险因素的研究进展[J]. 外科理论与实践, 2024, 29(04): 358-364. |
[3] | 宋子甲, 赵任. 早期直肠癌器官保留的研究进展[J]. 外科理论与实践, 2024, 29(03): 211-216. |
[4] | 谢海艇, 胡烨婷, 李军, 丁克峰. 局部进展期直肠癌的手术时机把握[J]. 外科理论与实践, 2024, 29(03): 206-210. |
[5] | 兰平, 陈永乐, 何晓生. 早期直肠癌的诊治现状与全程监测[J]. 外科理论与实践, 2024, 29(03): 197-205. |
[6] | 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 腹腔镜结肠直肠癌手术的标准化操作、质量控制与疗效评价[J]. 外科理论与实践, 2024, 29(03): 187-191. |
[7] | 张卫. 低位直肠癌适形切除规范手术操作标准(2023版)解读[J]. 外科理论与实践, 2024, 29(03): 217-219. |
[8] | 王雅琪, 夏凡, 章真. 局部进展期直肠癌新辅助放化疗联合免疫治疗的回顾和展望[J]. 外科理论与实践, 2024, 29(03): 220-229. |
[9] | 贾文清, 张弢, 赵任. 结肠直肠癌肿瘤疫苗研究现状及展望[J]. 外科理论与实践, 2024, 29(03): 264-269. |
[10] | 邵卫清, 陆录, 钦伦秀. 系统疗法改变肝癌外科的格局:机遇与挑战[J]. 外科理论与实践, 2024, 29(02): 93-98. |
[11] | 朱惠, 蔡继东, 李溟涵, 杨文涛, 徐烨. 结肠直肠癌错配修复蛋白表达与微卫星稳定性的一致性分析[J]. 外科理论与实践, 2024, 29(02): 148-155. |
[12] | 朱正纲. 联合抗血管生成、免疫检查点抑制剂与化疗在局部进展期胃癌新辅助治疗中的临床意义[J]. 外科理论与实践, 2024, 29(02): 132-137. |
[13] | 赵一鸣, 吴棕, 王鲁. 肝脏微环境细胞对结肠直肠癌肝转移的作用[J]. 外科理论与实践, 2024, 29(02): 126-131. |
[14] | 丁景峰, 敖炜群, 朱珍, 孙静, 徐良根, 郑世保, 俞晶晶, 胡金文. 基于T2WI和DWI的磁共振影像组学在术前预测直肠癌壁外血管侵犯的价值研究[J]. 诊断学理论与实践, 2024, 23(01): 46-56. |
[15] | 张太平, 翁桂湖, 刘悦泽. 可切除胰腺癌新辅助治疗的研究及指南解读,肯定还是否定?[J]. 外科理论与实践, 2024, 29(01): 1-4. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||